Soligenix, Inc. announced on October 22, 2024, that the Hong Kong Patent Office granted a patent titled 'Systems and Methods for Producing Synthetic Hypericin.' This patent covers a novel, highly purified form of synthetic hypericin, manufactured through a unique proprietary process.
Synthetic hypericin is the active pharmaceutical ingredient in HyBryte™, the company's photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and SGX302, a potential topical treatment for plaque psoriasis. This new patent (HK1260757) is related to previously issued U.S. and European patents and is expected to expire in 2036.
This patent strengthens Soligenix's intellectual property estate, providing enhanced protection for its key assets. The expanded patent coverage is a significant step as the company advances its confirmatory Phase 3 CTCL study and its ongoing Phase 2a psoriasis study toward potential commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.